About our business 54 % United States 22 % Europe 7 % China 18 % Rest of world FY21 revenue by segment Values in this exhibit reflect rounded numbers in billions of dollars $20.2 Total BD revenue BD Medical Medication Delivery Systems Medication Management Solutions Diabetes Care* Pharmaceutical Systems $9.5 $4.1 $2.4 $1.2 $1.8 BD Life Sciences Integrated Diagnostics Solutions Biosciences $6.5 $5.2 $1.3 BD Interventional Peripheral Intervention Surgery Urology and Critical Care $4.2 $1.7 $1.3 $1.2 * On April 1, 2022, BD e xecuted the spin of its Diabetes Care business, which is now a stand-alone and publicly traded company named Embecta Corp. (NASDAQ: EMBC). FY21 revenue by region 9 2021 ESG Report Appendices Transparency Healthy workforce and communities Responsible supply chain Product impact Climate change Introduction